

Toxicological Profile for Thorium

September 2019



CS274127-A

Agency for Toxic Substances and Disease Registry

DISCLAIMER

Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services.

FOREWORD

This toxicological profile is prepared in accordance with guidelines* developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a relevance to public health discussion which would allow a public health professional to make a real-time determination of whether the presence of a particular substance in the environment poses a potential threat to human health. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to the protection of public health are identified by ATSDR.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance due to associated acute, intermediate, and chronic exposures;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, intermediate, and chronic health effects; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.

Patrick N. Breysse, Ph.D., CIH Director, National Center for Environmental Health and Agency for Toxic Substances and Disease Registry Centers for Disease Control and Prevention

*Legislative Background

The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 104(i)(1) directs the Administrator of ATSDR to "...effectuate and implement the health related authorities" of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL) and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the NPL, in an effort to "...establish and maintain inventory of literature, research, and studies on the health effects of toxic substances" under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.

VERSION HISTORY

Date	Description
September 2019	Update of data in Chapters 2, 3, and 7
October 2014	Addendum to the toxicological profile
October 1990	Final toxicological profile released

CONTRIBUTORS & REVIEWERS

CHEMICAL MANAGER TEAM

Sam Keith, M.S., C.H.P.

David W. Wohlers, Ph.D. Lisa Ingerman, Ph.D., DABT

ATSDR, Division of Toxicology and Human Health Sciences, Atlanta, GA

SRC, Inc., North Syracuse, NY

REVIEWERS

Interagency Minimal Risk Level Workgroup:

Includes ATSDR; National Center for Environmental Health (NCEH); National Institute of Occupational Health and Safety (NIOSH); U.S. Environmental Protection Agency (EPA); National Toxicology Program (NTP).

Additional reviews for science and/or policy:

ATSDR, Division of Community Health Investigations; ATSDR, Office of Science; NCEH, Division of Laboratory Science; NCEH, Division of Environmental Health Science and Practice.

CONTENTS

DISCLAIM	MER	ii
FOREWO	RD	iii
VERSION	HISTORY	v
CONTRIE	BUTORS & REVIEWERS	vi
CONTEN	TS	vii
LIST OF I	FIGURES	ix
LIST OF 7	ΓABLES	X
CHAPTER	R 1. RELEVANCE TO PUBLIC HEALTH	1
1.1	OVERVIEW AND U.S. EXPOSURES	1
1.2	SUMMARY OF HEALTH EFFECTS	1
1.3	MINIMAL RISK LEVELS (MRLs)	3
CHAPTER	R 2. HEALTH EFFECTS	4
2.1	INTRODUCTION	
2.2	DEATH	
2.3	BODY WEIGHT	
2.4	RESPIRATORY	
2.5	CARDIOVASCULAR	24
2.6	GASTROINTESTINAL	24
2.7	HEMATOLOGICAL	25
2.8	MUSCULOSKELETAL	
2.9	HEPATIC	
2.10	RENAL	27
2.11	DERMAL	
2.12	OCULAR	
2.13	ENDOCRINE	
2.14	IMMUNOLOGICAL	
2.15	NEUROLOGICAL	
2.16	REPRODUCTIVE	
2.17	DEVELOPMENTAL	
2.18	OTHER NONCANCER	
2.19	CANCER	
2.20	GENOTOXICITY	
2.21	THOROTRAST	
CHAPTER	R 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEM	
	INTERACTIONS	
3.1	TOXICOKINETICS	
3.1.1	Absorption	
3.1.2	Distribution	
3.1.3	Metabolism	
3.1.4	Excretion	
3.1.5	Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	
3.1.6	Animal-to-Human Extrapolations	
3.2	CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY	
	SUSCEPTIBLE	
3.3	BIOMARKERS OF EXPOSURE AND EFFECT	
3.3.1	Biomarkers of Exposure	
3.3.2	Biomarkers of Effect	67

3.4 INTERACTIONS WITH OTHER CHEMICALS	
CHAPTER 4. CHEMICAL AND PHYSICAL INFORMATION	
4.1 CHEMICAL IDENTITY	
4.2 PHYSICAL AND CHEMICAL PROPERTIES	70
CHAPTER 5. POTENTIAL FOR HUMAN EXPOSURE	
5.1 OVERVIEW	
5.2 PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	79
5.2.1 Production	79
5.2.2 Import/Export	
5.2.3 Use	
5.2.4 Disposal	
5.3 RELEASES TO THE ENVIRONMENT	
5.3.1 Air	
5.3.2 Water	
5.3.3 Soil	
5.4 ENVIRONMENTAL FATE	
5.4.1 Transport and Partitioning	
5.4.2 Transformation and Degradation	
5.5 LEVELS IN THE ENVIRONMENT	
5.5.1 Air	
5.5.2 Water	
5.5.3 Sediment and Soil5.5.4 Other Media	
5.5.4 Other Media 5.6 GENERAL POPULATION EXPOSURE	
5.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	
5.7 POPULATIONS WITH POTENTIALL I HIGH EXPOSURES	
CHAPTER 6. ADEQUACY OF THE DATABASE	
6.1 Information on Health Effects	
6.2 Identification of Data Needs	
6.3 Ongoing Studies	
CHAPTER 7. REGULATIONS AND GUIDELINES	
CHAPTER 8. REFERENCES	
APPENDICES	
APPENDIX A. ATSDR MINIMAL RISK LEVELS AND WORKSHEETS	A-1
APPENDIX B. LITERATURE SEARCH FRAMEWORK FOR THORIUM	B-1
APPENDIX C. USER'S GUIDE	C-1
APPENDIX D. OVERVIEW OF BASIC RADIATION PHYSICS, CHEMISTRY, AND	
BIOLOGY	
APPENDIX E. QUICK REFERENCE FOR HEALTH CARE PROVIDERS	
APPENDIX F. GLOSSARY	
APPENDIX G. ACRONYMS, ABBREVIATIONS, AND SYMBOLS	G-1

LIST OF FIGURES

2-1.	Overview of the Number of Studies Examining Thorium Health Effects	9
2-2.	Levels of Significant Exposure to Thorium – Inhalation	14
2-3.	Levels of Significant Exposure to Thorium – Oral	19
3-1.	Respiratory Tract Compartments in Which Particles May be Deposited	55
3-2.	Environmental Pathways for Potential Human Health Effects from Thorium	57
3-3.	The Human Respiratory Tract Model: Absorption into Blood	62
3-4.	Structure of the Human Respiratory Tract Model (HATM)	63
4-1.	Uranium and Thorium Isotope Decay Series Showing the Sources and Decay Products of the Two Naturally Occurring Isotopes of Thorium	73
5-1.	Number of NPL Sites with Thorium and Thorium Compounds Contamination	76
6-1.	Summary of Existing Health Effects Studies on Thorium By Route and Endpoint 1	.06

LIST OF TABLES

1-1.	Minimal Risk Levels (MRLs) for Thorium	3
2-1.	Levels of Significant Exposure to Thorium – Inhalation	10
2-2.	Levels of Significant Exposure to Thorium – Oral	17
2-3.	Levels of Significant Exposure to Thorium – Dermal	21
2-4.	Standardized Mortality Ratios for All Cancers and Lung Cancers Among Male Thorium Workers	30
2-5.	Selected Thorotrast Treatment-Related Health Effects in Humans	36
3-1.	The Median Concentrations of Thorium Isotopes in Autopsy Samples from Grand Junction, Colorado, and Washington, DC (in pCi/kg Wet Weight)	45
3-2.	Reference Respiratory Values for a General Caucasian Population at Different Levels of Activity	56
3-3.	Reference Values of Parameters for the Compartment Model to Represent Time-dependent Particle Transport from the Human Respiratory Tract	58
4-1.	Chemical Identity of Thorium and Compounds	69
4-2.	Physical and Chemical Properties of Thorium and Compounds	71
4-3.	Percent Occurrence and the Energies of the Major Alpha Particles Emitted by Thorium Isotopes with Atomic Masses Ranging from 223 to 234	74
5-1.	Facilities that Produce, Process, or Use Thorium Dioxide	79
5-2.	United States Companies with Thorium Processing and Fabricating Capacity	80
5-3.	Releases to the Environment from Facilities that Produce, Process, or Use Thorium Dioxide	85
5-4.	Lowest Limit of Detection Based on Standards	92
5-5.	Summary of Environmental Levels of Thorium	93
5-6.	²³² Th Content in Fresh Fruits, Vegetables, and Tea	97
5-7.	Thorium Levels in Bones of Colorado and Pennsylvania Residents	98
5-8.	Thorium Isotopic Concentration in Three Occupational Cases and the General Population of Grand Junction, Colorado (pCi/kg)	99
7-1.	Regulations and Guidelines Applicable to Thorium	113